MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4274/tjh.galenos.2023.2023.0194

Медицинская библиотека · Turkish journal of haematology : official journal of Turkish Society of Haematology · 2023

Long-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study.

Savaş Emine Merve, Yılmaz Seda, Başer Dikyar Ayşe Asena, Özkurt Zübeyde Nur, Öcal Ramazan, Can Ferda, Pepeler Sezgin, Aydın Kaynar Lale, Gökçen Sanem, Yıldız Abdulkerim, Albayrak Murat, Karakuş Sema, Çeneli Özcan, Yağcı Münci

Многоцентровое исследованиеСтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

The discovery of imatinib was a milestone for chronic myeloid leukemia (CML). As the life expectancy of CML patients has approached that of the general population, research has shifted towards improving quality of life and economic considerations. After 2010, it was shown that some patients could maintain molecular response even after discontinuing imatinib. This national multicenter prospective cohort study aimed to observe the long-term consequences of discontinuing imatinib therapy in adult chronic-phase CML patients.

MATERIALS AND

METHODS

We enrolled 41 CML patients from 4 different centers in this non-randomized single-arm trial. Molecular responses of all patients were re-evaluated using real-time polymerase chain reaction at a single center. The median follow-up time after imatinib discontinuation was 48 months (minimum-maximum: 6-81 months).

RESULTS

The rate of molecular relapse-free survival at 48 months was 33.2% (confidence interval: 48.2-18.2). Twenty-seven of 41 patients lost their major molecular response, treatment was started again, and deep molecular response was re-achieved with imatinib in all cases. There was no significant relationship between molecular relapse and clinical factors such as duration of treatment or molecular response status. Discontinuing imatinib resulted in savings of approximately 4,392,000 Turkish lira or 245,150 US dollars.

CONCLUSION

Tyrosine kinase inhibitor discontinuation with close molecular monitoring is a safe option and provides important national economic benefits for chronic phase CML patients. This approach should be considered for all eligible patients. This is the first tyrosine kinase inhibitor discontinuation study from Türkiye.

Для цитирования: Savaş Emine Merve, Yılmaz Seda, Başer Dikyar Ayşe Asena, Özkurt Zübeyde Nur, Öcal Ramazan, Can Ferda, Pepeler Sezgin, Aydın Kaynar Lale, Gökçen Sanem, Yıldız Abdulkerim, Albayrak Murat, Karakuş Sema, Çeneli Özcan, Yağcı Münci. Long-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study.. Turkish journal of haematology : official journal of Turkish Society of Haematology. 2023. DOI: 10.4274/tjh.galenos.2023.2023.0194.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.